Community-Acquired Pneumonia (CAP) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032
Community-Acquired Pneumonia (CAP) is an acute pulmonary parenchymal infection in an individual who has not been hospitalized in the last 14-days and is not a resident of a nursing home or long-term care facility. The pathogen causing Community-acquired pneumonia is classified into; Typical agents (Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Group A Streptococci, anaerobes, and gram-negative organisms), and Atypical agents (Legionella, Mycoplasma, Chlamydia pneumoniae, and C. psittaci) globally. H. influenzae and S. pneumoniae are the two most common causes of bacterial pneumonia. Colonization of the pharynx with pathogens, followed by micro-aspiration, is the mechanism of entry into the lower respiratory tract. Other mechanisms include hematogenous spread and macro-aspiration. In the interaction between the pathogen and host pulmonary defence, pneumonia develops if the host defence is weak or overcome by high inoculum or virulence of the pathogen.
·
The incidence of Community-Acquired Pneumonia
(CAP) in the USA ranges from 28 to 57 per 10,000 population in the USA.
Thelansis’s “Community-Acquired
Pneumonia (CAP) Market Outlook, Epidemiology, Competitive Landscape, and Market
Forecast Report – 2022 To 2032" covers disease overview, epidemiology,
drug utilization, prescription share analysis, competitive landscape, clinical
practice, regulatory landscape, patient share, market uptake, market forecast,
and key market insights under the potential Community-Acquired Pneumonia (CAP)
treatment modalities options for eight major markets (USA, Germany, France,
Italy, Spain, UK, Japan, and China).
KOLs insights
of Community-Acquired Pneumonia (CAP) across 8 MM market from the centre of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Community-Acquired Pneumonia (CAP) Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment